Aethlon Medical CEO Frakes receives 42,000 RSUs under 2020 equity incentive plan
AEMD•Aethlon Medical granted CEO and CFO James B. Frakes 42,000 restricted stock units on Oct. 8, 2026. The award vests over one year, subject to continued service, and accelerates to full vesting if the proposed merger with North Immunology closes.
1. Grant details
Aethlon Medical disclosed that it granted 42,000 restricted stock units to CEO and CFO James B. Frakes on Oct. 8, 2026, under its amended 2020 Equity Incentive Plan. The units vest over the following year, subject to continued service, and vest fully upon closing of the proposed merger with North Immunology.
